Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's Hasico Secures China Rights to Microbion's Chronic Wound Product

publication date: Mar 9, 2016
Haisco Pharma secured China rights to a novel treatment for chronic wounds developed by Microbion, a US-Canada biopharma. To gain the rights, Haisco made an investment of undisclosed size in Microbion. The drug, MBN-101, is a clinical-stage product in the bismuth-thiol class aimed at treating resistant and difficult-to-treat infections, including biofilms. Haisco will be responsible for China regulatory work and commercialization of MBN-101. More details....

Stock Symbol: (SHZ: 002653)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital